A management shakeup isn’t the only issue facing Raleigh diagnostics firm LipoScience (Nasdaq: LPDX), which once again finds itself at odds with the Food and Drug Administration. The newly public company is voluntarily withdrawing its application to market a new blood test, but isn’t giving up on the product. Specifically, LipoScience is withdrawing its 510 (k) filing to market a high-density lipoprotein particle (HDL-P) test, which measures certain blood particles in order to better manage heart disease.
Help employers find you! Check out all the jobs and post your resume.
